- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 1,595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 85
- States / cities
- Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 14,761
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- naquotinib mesilate, Erlotinib, Gefitinib
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 25
- States / cities
- Beverly Hills, California • Fountain Valley, California • La Jolla, California + 21 more
- Conditions
- COVID-19
- Interventions
- STX-S
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Rochester, New York • Seattle, Washington
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- afatinib, loperamide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 12
- States / cities
- Santa Rosa, California • Orlando, Florida • Port Saint Lucie, Florida + 7 more
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer
- Interventions
- NT-I7, pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- NeoImmuneTech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Dextrose
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Elliott, Maryland
- Conditions
- Small Cell Lung Cancer
- Interventions
- IMGN901, Carboplatin and Etoposide
- Drug
- Lead sponsor
- ImmunoGen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 23 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, Noninvasive Ventilation
- Interventions
- Noninvasive Ventilation
- Device
- Lead sponsor
- San Francisco Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer
- Interventions
- Nivolumab, oral decitabine, Tetrahydrouridine
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Cleveland, Ohio
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, mRNA-1273.231
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,161 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 23
- States / cities
- Sacramento, California • Hollywood, Florida • Jacksonville, Florida + 18 more
- Conditions
- Asthma, Obesity
- Interventions
- Mitoquinol, Placebo oral tablet
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Burlington, Vermont
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Eribulin, TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Pleasant Hill, California • San Diego, California + 10 more
- Conditions
- Cystic Fibrosis, Exocrine Pancreatic Insufficiency
- Interventions
- EUR-1008 (APT-1008)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- Up to 7 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 11 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
- Interventions
- LOXO-260
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more
- Conditions
- Acute Respiratory Distress Syndrome, Neuromyopathies
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Asthma
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Advanced Malignancies, Non-small Cell Lung Cancer
- Interventions
- MGCD265+erlotinib, MGCD265+docetaxel
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Durham, North Carolina • Philadelphia, Pennsylvania + 2 more
- Conditions
- Mycobacterium Infections
- Interventions
- Clofazimine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthcare-Associated Pneumonia, Sepsis
- Interventions
- antimicrobial initiation
- Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Transplantation, Lung
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Long-term Effects Secondary to Cancer Therapy in Children, Pulmonary Complications
- Interventions
- management of therapy complications
- Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cystic Fibrosis
- Interventions
- Acute Antioxidant, Chronic Antioxidant, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Covid19, Cognitive Impairment
- Interventions
- AKL-T01, Control Group
- Behavioral · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee